Abstract
Objective: This prospective study was designed to evaluate whether human papillomavirus (HPV) DNA testing is a cost-effective tool in the management of women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL) detected by Papanicolaou (Pap) smear. Material(s) and Method(s): Our study included a total of 513 women with ASCUS or LSIL detected by Pap smear. All then had a repeat Pap smear, HPV DNA testing, and colposcopically directed biopsies. The methods were compared with regard to sensitivity for detecting high-grade cervical intraepithelial neoplasia (CIN) and cost. Result(s): The sensitivity of HPV DNA for high-grade CIN or invasive cancer was 90.2% (37/41) for ASCUS and 95.4% (62/65) for LSIL, whereas the corresponding values for repeat Pap smears were only 71.8% (28/39) and 76.2% (48/63). In 128 women with ASCUS whose biopsy results were normal or had low-grade CIN, a positive HPV DNA test was helpful in predicting those who subsequently developed high-grade CIN. While repeat Pap smear testing was the least expensive method (NTD 11051/case of high-grade CIN detected), it was also the least sensitive. Colposcopic biopsy was less expensive than HPV DNA testing (NTD 14,034 vs. 18,709). Conclusion(s): While HPV DNA testing is sensitive in predicting concurrent and subsequent high-grade lesions, its role is limited by its cost. Colposcopic biopsy is the most cost-effective first step in evaluating women with ASCUS and LSIL. In women with high-grade CIN, therapy should be given on that basis. However, in women with ASCUS, if the biopsy results are normal or low-grade CIN, HPV DNA testing at that point is useful to predict which women will require closer follow up. In women with LSIL but with low-grade CIN on biopsy, there is no need to test for HPV since almost all will be positive, and they are suggested to perform colposcopy directly.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.